CD133 is a pivotal marker of cancer stem cells (CSCs), which is involved in tumorigenesis and cancer progression. Recent studies have identified CD133 to be a prognostic factor for cancer rested with its expression and genetic variants. Here, we hypothesized that the single nuclear polymorphisms (SNPs) in CD133 may be associated with lung cancer risk and prognosis. Based on three independent case-control analyses with a total of 2332 lung cancer cases and 2457 controls, the gene-based association analysis with 13 polymorphisms of CD133 suggested that CD133 is a susceptible gene for lung cancer (P = 0.043) and that the SNP rs2240688A>C in the 3′-untranslated region of CD133 is the most significant associated SNP with the risk of lung cancer (P = 0.020); further analysis showed that the rs2240688C variant genotypes (CA+CC) harbored a decreased risk of lung cancer (odds ratio = 0.80; 95% confidence interval (CI) = 0.72-0.90) and conferred a favorable survival for lung cancer patients (median survival time: 15 months) compared with AA genotype (median survival time: 11 months, logrank test: P = 3.31 × 10 -6 ; Cox model: hazards ratio = 0.81, 95% CI = 0.70-0.94). Functional assays revealed that the rs2240688A to rs2240688C transition gained a new binding of the microRNA hsamiR-135a/b and decreased the CD133 expression. Our data suggest that the functional polymorphism rs2240688A>C in CD133 is associated with lung cancer risk and survival. This SNP may be a functional biomarker to predict risk and prognosis of lung cancer.
Introduction
Lung cancer is the most common cause of cancer-related death in China and in the world, with a high incidence and mortality (1, 2) . The pathological mechanism of lung cancer is extremely complex, involving the environmental and genetic factors. In spite of the continuous efforts to improve the therapeutic response, the prognosis for lung cancer patients is still very poor, with an overall 5-year survival rate less than 16% (3) . The cancer stem cells (CSCs) are a small population of cancer cells that are responsible for tumor initiation, maintenance, metastasis (4) (5) (6) (7) (8) (9) , relapse and drug resistance (10, 11) .
It is conceivable that genetic variants in genes about CSCs may have effects on cancer development and progression and thus are related to cancer risk and prognosis.
CD133 (also known as PROM1; MIM: 604365) is recognized as an important cell surface marker of CSCs and has been used to enrich the stem-like population in various human tumors, among which is lung cancer (12) (13) (14) . CD133 is specifically located in cellular protrusions and is involved in cell-cell interactions and mature organ homoeostasis (15, 16) . Previous studies have shown that CD133 could contribute to tumorigenesis and metastasis by virtue of CSCs property. Compared with CD133 -cells, CD133 + cells showed high tumorigenic capacity in lung carcinogenesis by promoting expression of other genes that involved stemness, adhesion, motility and drug efflux (17) . High CD133 expression is associated with poor prognosis of various tumors, including lung cancer (18) , colon cancer (19) , brain tumor (20) , liver cancer (21) , endometrium (22) and ovary cancer (23) . Moreover, high CD133 expression induces tumors to resist to cisplatin treatment in lung cancer therapy (17) .
Human CD133 gene is located on chromosome 4p15, a region identified to be susceptible to human cancers, including lung cancer (24) (25) (26) . Genetic variants in the CD133 genes have been reported to be associated with various human diseases in several genome-wide association studies (GWAS), such as self-rated health, human immunodeficiency virus-1 infection and type 2 diabetes (http://jjwanglab. org:8080/gwasdb/) (27) (28) (29) (30) . Recently, two single nuclear polymorphisms (SNPs), rs2286455 and rs3130 in CD133, were reported to be associated with the prognosis of colorectal cancer (31) . However, the previous GWAS reported SNPs were all located in introns of CD133, which may lack function, and by now, little is known about the function of CD133 SNPs. The expression of CD133 is positively correlated with development of lung cancer (18, 32) . Therefore, we hypothesized that those putative functional SNPs in CD133 may influence the function of CD133 and consequentially lung cancer risk and prognosis.
In this study, we investigated the associations between 13 putative functional SNPs in CD133 and both the risk and the survival of lung cancer in southern Chinese. Then we validated promising associations in other two independent case-control studies of southern and eastern Chinese populations. Consecutive functional assays were further performed to determine the biological effects of these polymorphisms.
Materials and methods

Study subjects
This study included three independent case-control studies with a discovery set and two validation sets as described previously (33) . In brief, the discovery set included 1056 histopathologically confirmed lung cancer cases with a 95% response rate (in response to the whole patients diagnosed in the investigatory hospitals) and 1056 age (±5) and sex frequency-matched cancer-free controls with a response rate of 84% (in response to the whole interviewees). All of whom were recruited from Guangzhou city. The validation set I, also from Guangzhou city, included another 773 lung cancer cases with an 89% response rate and 778 cancer-free controls with an 83% response rate. The validation set II, from Suzhou City, included 503 lung cancer cases with a response rate of 87% and 623 frequency-matched controls with an 81% response rate. All patients were followed up every 3 months using telephone calls. Also, their date of death, if applicable and that the deaths are directly caused by lung cancer, was obtained from medical records or from patients' families. Finally, excluding the lost populations, the populations used for prognosis analysis are 510 patients with complete survival data from the discovery set, 331 cases from the validation set I and 296 cases from the validation set II. All subjects were unrelated Han Chinese. Each participant was scheduled for an interview after a written informed consent was obtained to provide data on smoking status and other factors with a structured questionnaire. Participants were also asked to donate a 5 ml peripheral blood sample. The definitions of smoking status, pack-years smoked, alcohol use, the family history of cancer and others have Abbreviations: ANOVA, analysis of variance; CI, confidence interval; CSC, cancer stem cell; GWAS, genome-wide association studies; HR, hazards ratio; OR, odds ratio; SNP, single nuclear polymorphism; UTR, untranslated region.
CD133 SNPs' associations with lung cancer risk and survival been described elsewhere (34) (35) (36) . This study was approved by the institutional review boards of Guangzhou Medical University and Soochow University.
SNPs selection and genotyping
Based on the dbSNP database (http://www.ncbi.nlm.nih.gov/), all reported SNPs in the CD133 gene with a minor allele frequency >5% in Chinese populations were included (Supplementary Figure S1 , available at Carcinogenesis Online). Among these SNPs, all putative functional SNPs (13 SNPs) that are located in the promoter, exon and 3'-untranslated region (UTR) of the CD133 gene were selected and genotyped in our study. Genomic DNA was isolated from the peripheral blood lymphocytes of the study subjects. MassArray (Sequenom, San Diego, CA) was used for genotyping the 13 SNPs in the discovery set using allele-specific matrix-assisted laser desorption-time of flight mass spectrometry by commercial company (Biomiao Biological Technology, Beijing, China). Then the promising SNPs were further genotyped in the validation sets with MassArray (Sequenom). 10% of the samples were randomly selected to repeat to confirm the genotyping results, and the results were in 100% agreement.
Construction of luciferase reporters
Based on the fact that a significant association was observed between the SNP rs2240688A>C and lung cancer risk and bioinformatics analysis (SNPinfo Web server: http://snpinfo.niehs.nih.gov/) showed that the rs2240688A to rs2240688C transition gained a new binding of the microRNA hsa-miR135a/b or has-miR-942, we constructed three reporter plasmids containing rs2240688A or rs2240688C allele or a mutated sequence to determine whether this polymorphism had any effect on gene's expression. The A allele reporter construct was prepared by amplifying the 1143 bp 3′-UTR of CD133 (+1 nucleotide to +1143 bp downstream to the translation stop site TAA) from subject with homozygous AA genotype using the forward primers: 5′-CCG ctc gag CAT CAG GAT ACT CAA AGT GGA AAG G-3′ and reverse primer: 5′-AAG GAA AAA Agc ggc cgc CAT GTT TTC CAA GTT CCT TTT TAT TCA -3′, including the XhoI and NotI restriction sites (i.e. lower case nucleotid was the enzyme restriction site). The PCR products and Psi-CHECK2 basic vector (Promega, Madison, WI) were cleaved by using XhoI and NotI (New England BioLabs) and then ligated by T4 DNA ligase (New England BioLabs) to produce a CD133-Psi-CHECK2 reporter gene. The renilla luciferase was used to show the transcriptional activity of the 3′-UTR of CD133 gene, and the firefly luciferase was used as the internal standard. The C allele reporter construct, and a referenced constructs with a mutated hsa-miR-135a/b binding site, was obtained from the 'A' construct by site-directed mutagenesis using the Quick-Change site-directed mutagenesis kit (Stratagene, La Jolla, CA). We sequenced all reporter constructs to confirm the sequence, orientation and integrity of each insert.
RNA interference, transient transfections and luciferase assays
We applied the mimics and inhibitors of the predicted two microRNAs that were synthesized by GenePharma Co (Shanghai, China) to show their effect on CD133-Psi-CHECK2 reporter genes in vitro. Two human lung cancer cell lines, A549 and NCI-520, were cultured in Roswell Park Memorial Institute 1640 medium with 10% fetal bovine serum (Sigma-Aldrich, MO) at 37°C in 5% CO 2 . The luciferase assays were performed as described previously (34, 35) . Briefly, cells plated on 24 well plates were transiently transfected with 0.5 μg of reporter plasmids (A or C allele) alone or cotransfected with microRNA mimics or inhibitors using Lipofectamine 2000 (Invitrogen, Carlsbad, CA). The activities of CD133-Psi-CHECK2 reporter were quantified by a Dual-Luciferase Reporter Assay System (Promega, Madison, WI). Independent triplicate experiments were done for each plasmid construct.
Real-time PCR
Thirty-two lung cancer tissues and their adjacent normal tissues were collected during the surgical excision from the first hospital, second hospital and the tumor hospital affiliated to Guangzhou Medical University. Total RNA was isolated with the Trizol Reagent (Invitrogen), and 2 µg total RNA was then reversely transcribed to complementary DNA using random primers and Superscript II (Invitrogen). Relative messenger RNA (mRNA) expression for CD133 was quantified using the ABI Prism 7500 sequence detection system based on the Taqman method with self-designed primers and probe, and β-actin was used as an internal reference gene (Supplementary Table S1 , available at Carcinogenesis Online). Method of 2
∆t was used to demonstrate the level of CD133 gene's expression. We also detected the effect of the operant microRNA on the expression of CD133 in cell lines with real-time PCR analysis. Because of the fact that all cell lines that we detected were of the same genotype, we used three peripheral lymphocytes that were obtained by Ficoll-Hypaque from three genotype-identified samples (i.e. AA, CA, CC genotype). The mRNA levels were detected in the followed 48 and 72 h after treatment with the microRNA mimics or inhibitors, respectively.
Because the hsa-miR-135a/b was identified to modify the function of the associated SNP rs2240688A>C, we further detected its expression in cell lines and lung cancer tissues. The Taqman microRNA Assays (Applied Biosystems) was used to detect microRNA expression. Quantitative real-time PCR was performed with the gene-special primers, Taqman stem-loop kit and the Taqman Universal PCR Master (Applied Biosystems) using the Applied Biosystems ABI 7500 real-time PCR system according to the manufactures' protocol. The expression level of U6 small nuclear RNA was used as an internal reference to calculate the relative expression of miR-135a/b. All analyses were performed in a blinded fashion, which means that the laboratory persons were unaware of the genotyping data, and each assay was done in triplicate.
Western blot analysis
Proteins were extracted from the formerly described 32 lung cancer tissues, and the western blot analysis was performed as described previously (34, 35) . Briefly, the samples were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and electrotransferred onto polyvinylidene fluoride membranes. After blocked with 5% skim milk, the membrane was incubated with anti-CD133 antibody (1:1000) and the proteins were detected with a phototope-horseradish peroxidase western blot detection kit (Cell Signaling Technology, Danvers, MA). The relative CD133 protein expressions normalized to β-actin were semiquantified with a software Gene Tools (version 4.01; Syngene, Cambridge, UK) assembled in our image machine (G:BOX; Syngene). The antibodies against CD133 (Catalog#: PAB12663: rabbit polyclonal antibody, a synthetic peptide corresponding to amino acids 798-864 at C-terminus of human PROM1) and β-actin [Catalog#: H00000060-M01: mouse monoclonal antibody, ACTB (AAH01301, 1 amino acid ~ 375 amino acids) full-length recombinant protein with glutathione S-transferase tag. MW of the glutathione S-transferase tag alone is 26 kDa] were purchased from Abnova Corporation.
Immunohistochemistry
Fifty-four lung cancer tissues were collected from the tumor hospital affiliated to Guangzhou Medical University and from the first hospital affiliated to Soochow University. Immunostaining was performed through the streptavidin-peroxsidase method that uses liquid diaminobenzidine reagent, within which 3, 3′-diaminobenzidine tetrahydrochloride was the chromogen, and hematoxylin was the counterstaining reagent as described previously (33) . Immunostaining was performed by streptavidin-peroxsidase method. In detail, sections were dewaxed, and rehydrated by sequential immersion in xylene, graded ethanol and water. Then the sections were boiled in 10 mmol/l citrate buffer (pH 6.0) in a microwave oven for antigen retrieval. Endogenous peroxidase activity was blocked with 3% hydrogen peroxide in methanol, and non-specific binding was blocked by incubating with 10% normal goat serum for 20 min. Sections were incubated overnight at 4°C with primary antibody of CD133 (1:100; Abnova). After washing with phosphate-buffered saline, biotinylated goat anti-rabbit IgG was applied to the sections at room temperature for 30 min, rinsed with phosphate-buffered saline and followed by an avidinbiotin-peroxidase conjugate for 30 min at room temperature. Reaction products were observed by incubation with diaminobenzidine. Negative controls were treated identically but with the primary antibodies omitted. The immunohistochemical reactions were then visualized under high-power magnification (×200) using an Olympus microscope. Meanwhile, all tissue samples were genotyped. In cancerous tissues, particles that shared brown color indicated CD133 protein expression, which is localized mainly in the cell membrane surface and in some parts of the cytoplasm of tumor cells. In scoring expression of CD133 protein, staining intensity score was obtained from the Image Pro Plus software IPP, and percentage of positive cells examined was scored as 0 (negative), 1 (<10%), 2 (11-50%), 3 (51-80%) and 4 (>80%). Two independent pathologists are obtaining these scores simultaneously. The intensity score multiplied the percentage score to represent the relative level of CD133 expression. These discordant scores between two pathologists were reanalyzed by another pathologist.
Statistical analysis
The chi-square test was used to assess differences in the distributions of CD133 genotypes and selected variables between cases and controls and to assess the Hardy-Weinberg equilibrium test in cancer-free controls. The unconditional logistic regression model was used to estimate the associations between the SNPs and cancer risk with adjustment for age, sex, pack-years smoked, drinking status and family history of cancer. The log-rank test, Cox model with adjustment for age, sex, pack-years smoked, stages, surgery, chemotherapy and radiotherapy status were used to analyze the CD133 SNPs' effect on lung cancer survival. The multiplicative interaction model was used to assess the possible interaction between CD133 genotypes and surrounding factors on cancer risk and survival (34) . Breslow-Day test was used to test the homogeneity among three centers and among strata-ORs in stratification analysis. The VEGAS software was used to test the gene-based association analysis (37) . We performed sensitive analysis on analyzing the effect of rs2240688A>C SNP separately for the patients with or without survival data. The PS Software (http://biostat.mc.vanderbilt.edu/twiki/bin/view/Main/ PowerSampleSize) was used to calculate the statistical power. Student's t-test was used to compare the differences in luciferase reporter gene expression levels. The one-way analysis of variance (ANOVA) test and the linear regression model, which has been adjusted for surrounding factors, were used to evaluate the association between CD133 genotypes and CD133 expression. All tests were two-sided by using the SAS software (version 9.3; SAS Institute, Cary, NC), and P < 0.05 was considered statistically significant.
Results
Association between CD133 SNPs and lung cancer susceptibility
The distribution of demographic characteristics of the study populations were shown in Supplementary Table S2, available at Carcinogenesis Online. Consistently, lung cancer cases were more likely to be of smokers with more pack-years smoked compared with controls in all populations (P < 0.05 for all). The homogeneous test further showed that the frequency distributions of smoking status, pack-years smoked and drinking status were not homogeneous among the three sets (P < 0.05 for all).This possibly reflects different lifestyles among these three populations.
As shown in Table I , in the discovery set, the genotype distributions of the 13 SNPs in controls were all in Hardy-Weinberg equilibrium (P > 0.05 for all). Based on the additive model, we only found that the SNP rs2240688A>C in the 3′-UTR of CD133 was significantly associated with a decreased risk of lung cancer (P = 0.007). Compared with the common rs2240688AA genotype, the variant rs2240688CA or rs2240688CC genotype contributed to a 19 or 29% decreased risk of lung cancer, respectively [odds ratio (OR) = 0.81, 95% confidence interval (CI) = 0.68-0.98, P = 0.026 for CA genotype; OR = 0.71, 95% CI = 0.52-0.99, P = 0.041 for CC genotype]. Moreover, the rs4698134GA heterozygote had a significantly increased risk of lung cancer (OR = 1.23; 95% CI = 1.03-1.48, P = 0.026) of the SNP rs4698134A>G compared with that of the rs4698134AA genotype. However, the relevance of other SNPs was not significant (P add > 0.05 for all). Based on the P value of the above 13 SNPs, we performed the gene-based association analysis with the VEGAS software; the results suggested that CD133 is a susceptible gene for lung cancer (P = 0.043), and the SNP with the most significant relevance to lung cancer risk is rs2240688 (P = 0.020) (37) .
We further verified the association between SNP rs2240688A>C and lung cancer risk in the validation sets. Consistently, the SNP was significantly associated with lung cancer risk in both sets (I: P = 0.022; II: P = 0.049) under the additive model. Compared with the individuals who carry the rs2240688AA genotype, those carrying the rs2240688C (CA+CC) genotypes had a 20% decreased risk of lung cancer in validation set I (OR = 0.80, 95% CI= 0.65-0.98, P = 0.031) and 20% decreased risk in validation set II (OR = 0.80, 95% CI = 0.63-1.02, P = 0.069; Table II ). Because of the fact that all above associations were homogeneous (P = 0.811), we merged them to increase the study power and found that the rs2240688C genotypes caused lung cancer risk to fall by 20% (OR = 0.80, 95% CI = 0.72-0.90, P = 2.00 × 10 −4 ). However, in stratification analysis, the homogeneity test and interaction test showed no significant difference between stratum-ORs and interaction between risk factors and rs2240688C genotypes (P > 0.05 for all, Supplementary Figure S2 , available at Carcinogenesis Online).
The CD133 rs2240688A>C genotypes and lung cancer survival
The effects of characteristics and clinical features of patients on lung cancer survival were presented in Supplementary Table S3 , available at Carcinogenesis Online. The age, sex, smoking status, pack-years smoked, surgical operation, chemotherapy, radiotherapy and clinical stages were all significantly associated with lung cancer survival (log rank, Cox model: P < 0.05 for all). In addition, the sensitivity analysis showed similar results in patients with survival data (OR = 0.78, 95% CI = 0.67-0.90) and in those without (OR = 0.83, 95% CI = 0.72-0.97; homogeneity test: P = 0.500).
As shown in Table III and Figure 1 , the rs2240688C genotypes conferred a significantly favorable survival of lung cancer patients, the median survival time of patients who carry rs2240688C genotypes in the discovery set was significantly longer (13 months) than those with AA genotype (10 Months, log-rank test: P = 0.001) and these patients had a decreased hazard of death rate with a statistically borderline significance (Cox model: adjusted hazards ratio (HR) = 0.83, 95% CI = 0.68-1.00, P = 0.052; Figure 1A ). The results from the validation sets further confirmed above findings. In validation set I, individuals carrying rs2240688C genotypes had a 4 month increase in median survival time compared with the AA genotype (18 months versus 14 months, log-rank test: P = 0.029; Figure 1B ) and decreased death rate (HR = 0.73, 95% CI = 0.51-1.04, P = 0.087; Table III); the same occurred in validation set II (CA+CC versus AA: 17 months versus 13 months, log-rank test: P = 0.012; Figure 1C ; Cox model: HR = 0.71, 95% CI = 0.52-0.96, P = 0.026). We then merged the three populations and found that rs2240688C genotypes conferred a 4 month increase in median survival time compared with the AA genotype (15 months and 11 months, respectively; log-rank test: P = 3.31 × 10 -6 ) and had a 19% lower death risk (Cox model: HR = 0.81, 95% CI = 0.70-0.94, P = 0.004; Table III ). Furthermore, there was a significant interaction between family history of cancer and the rs2240688C genotypes on lung cancer survival (P = 0.020; Supplementary Figure S3 , available at Carcinogenesis Online) as shown in the stratification analysis. Furthermore, the multivariate Cox model showed that age, pack-years smoked, stages, surgery, chemotherapy, radiotherapy and rs2240688 genotypes remained significantly associated with lung cancer survival (Supplementary  Table S4 , available at Carcinogenesis Online).
Effect of the SNP rs2240688A>C on reporter gene's activity and treatment of microRNAs
Two luciferase reporter gene constructs containing rs2240688A or rs2240688C allele were generated. The transcription activity of reporter gene with rs2240688C allele was significantly lower than that with rs2240688A allele in both cell lines (P = 0.005 for A549, P = 0.003 for NCI-520, Figure 2A) . In response to the referenced constructs, the hsa-miR-135a/b mimics could significantly decrease activity of reporter gene with the rs2240688C allele than A allele (P = 0.012 for A549 and P = 0.002 for NCI-520). Also, the hsamiR-135a/b inhibitors significantly reversed the activity of reporter gene with the rs2240688C allele (P = 0.002 for A549 and P = 0.013 for NCI-520) but not A allele. However, we did not observe any significant effects on the reporter genes' activities with either C or A allele (data not shown) with treatment of the mimic and inhibitor The observed genotype frequencies among the control subjects were all in agreement with the Hardy-Weinberg equilibrium in the control subjects (P > 0.05 for all). of hsa-miR-942. In addition, we had detected a baseline expression of hsa-miR-135a/b in the two cell lines ( Figure 2B ). We found an expression of hsa-miR-135a/b in both A549 and NCI-520 cells, which indicated that the above effect of hsa-miR-135a/b on differently regulating reporter genes is possible.
Effects of the hsa-miR-135a/b on CD133 gene's expression
As shown in Figure 2C , we found that the mimics of miR-135a/b could specially suppress the mRNA expression of CD133 in peripheral blood lymphocytes with rs2240688CC or rs2240688CA genotype (P < 0.001 for both) but not in that with rs2240688AA genotype (P = 0.116). The treatment of miR-135a/b inhibitors trended to reverse and upregulate the CD133 expression in peripheral blood lymphocytes with rs2240688CA or rs2240688CC genotype, but the differences are not significant (P = 0.086, and 0.102, respectively). Moreover, there was a trend of negative correlation between miR-135a/b expression and CD133 expression in the 18 cases of tissues carrying rs2240688C genotypes. However, this trend was not statistically significant (r = −0.103, P = 0.369; data not shown). 
CD133 SNPs' associations with lung cancer risk and survival
Association between CD133 rs2240688A>C genotypes and CD133 expression As shown in Figure 3A , we found that the mRNA levels of CD133 in 32 lung cancer tissues were significantly higher than their adjacent normal tissues (student's t-test: P = 0.047). We further found that the CD133 mRNA levels were inversely correlated with the number of rs2240688C allele (ANOVA test: P = 0.047; lineal regression: P = 0.014; Figure 3B ). The CD133 protein expression in 32 lung cancer tissues confirmed the above findings as shown in Figure 3C , and the tissues with rs2240688C genotypes (CA or CC) harbored a significantly lowered CD133 expression compared with those with rs2240688AA genotype (ANOVA test: P = 0.045; lineal regression: P = 0.022). This result was consistent with the protein expression in situ, as shown by the immunohistochemistry assays in 54 lung cancer tissues (ANOVA test: P = 0.035; lineal regression: P = 0.021; Figure 3D ).
Discussion
In this study, we found that the rs2240688C genotypes in the 3′-UTR of CD133 was significantly associated with a decreased risk of lung cancer; the genotypes also conferred a favorable survival for lung cancer patients in three independent case-control studies. We further identified that the rs2240688C variants can significantly decrease the expression of the CD133 gene, and the posttranscriptional factor, hsamiR-135a/b but not hsa-miR-942, may play a pivotal role in modulating the effect of the SNP on CD133 expression. To the best of our knowledge, this is the first study to indicate that the genetic variants in CD133 may predict the risk and survival of lung cancer. CD133 has been identified as a pleiotropic marker of CSCs in various human tumors. Both clinical analyses and laboratory studies have shown that CD133 plays a critical role in tumorigenesis and tumor progression (38, 39) . Increased CD133 expression was observed in several human cancer tissues (40, 41) and was reported to be associated with poor prognosis of cancer patients (18, (20) (21) (22) . Lung CSCs play important roles in lung tumor initiation, maintenance and metastasis (4) (5) (6) (7) (8) (9) . CD133 is an important surface marker of lung CSC; CD133 + cells carry out stem cells' intrigues and exert higher tumorigenic capacity in lung cancer (17) . Therefore, corresponding to effect of lung CSCs, CD133 is involved in the initial phase of malignance, maintenance, metastasis and drug resistance of lung cancer (42) . Consistently, high CD133 expression confers a significantly higher risk of recurrence and poor survival of lung cancer (18, 32) . In this study, we consistently found that the expression of CD133 was higher in lung cancer tissues than in their normal adjacent tissues. We also found that the rs2240688C genotypes decreased the CD133 expression, which might decreased the number or undermine the biological function of lung CSCs and thus harbored a decreased risk and favorable survival of lung cancer. Meanwhile, the gene-based analysis identified the CD133 gene as a susceptible gene for lung cancer and the SNP rs2240688A>C with most significance. All these indicated that the genetic effect of CD133, which corresponds to rs2240688A>C genotypes, was associated with lung cancer risk and survival in Chinese.
Functional analyses showed that the locus rs2240688C was the binding site of hsa-miR-135a/b, and rs2240688AC or rs2240688CC variant genotypes had specially decreased expression of CD133. Interestingly, downregulated hsa-miR-135a/b has been reported in several cancers (43) . Furthermore, the non-significant trend of negative correlation between miR-135a/b expression and CD133 expression suggested that there may be some unrecognized mechanisms on modulating the miR-135a/b' effect on rs2240688C genotypes, such as host factors or gene-environment interaction. All in all, it would be possible that microRNA hsa-miR-135a/b binds to the locus of rs2240688C allele, suppresses the expression of CD133 and thus decreases the cancer risk and favors survival of lung cancer patients.
Recently, GWAS have identified several SNPs in CD133 to be associated with various human diseases (27) (28) (29) (30) . However, studies on CD133 SNPs and cancer risks and prognosis are few. There was only one study that reported two SNPs in CD133 showed a significant association with colorectal cancer patients' survival (31) . Here, based on the candidate gene hypothesis, we tested the association between 13 putative functional SNPs and lung cancer risk in discovery set and then validated the promising association in other two independent populations. We found that the CD133 rs2240688C genotypes exerted a decreased risk and conferred a favorable survival of lung cancer. This is also consistent with the previous lung cancer GWAS conducted in Chinese, which showed that rs2240688A>C was significantly associated with lung cancer risk (the SNP was not reported due to the high genome-wide significance, P = 0.044) (44) . Furthermore, the genetic effect of rs2240688A>C on lung cancer survival was lost in subjects with history of lung cancer and had a negative interaction with it, reflecting the SNP to be an inheritable feature. All these suggest that the SNP rs2240688A>C of CD133 may be a genetic biomarker for lung cancer.
This study has several strengths. Based on a multiple large-scale population including southern and eastern Chinese, we have gained consistent results of the association between the SNP rs2240688A>C and lung cancer risk and survival, with study power more than 97.5% for risk analysis and 97.0% for survival analysis. The SNP rs2240688A>C is functional, further proving that our results were not achieved by chance. However, being hospital-based case-control studies and the study populations restricted to Chinese Han, some selection bias is unavoidable in this study.
In conclusion, we found a significant association between the SNP rs2240688A>C of CD133 and lung cancer risk and survival. It was inversely correlated with CD133 gene expression via the modulation of hsa-miR-135a/b. Our findings suggest that the SNP rs2240688A>C may be a functional biomarker to predict the risk and survival of lung cancer. Validations with larger population-based studies in different ethnic groups are warranted.
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